Cx Institutional Amgen Inc Transaction History

Cx Institutional

$2.65 Billion
Q1 2025

A detailed history of Cx Institutional transactions in Amgen Inc stock. As of the latest transaction made, Cx Institutional holds 37,026 shares of AMGN stock, worth $10.7 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares

37,026

Previous 40,436 8.43%

Holding current value

$10.7 Million

Previous $10.5 Million 9.46%

% of portfolio

0.44%

Previous 0.42%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 15, 2025	SELL	$258.59 - $327.36 $881,791 - $1.12 Million	-3,410 Reduced 8.43%	37,026 $11.5 Million
Q4 2024 Jan 21, 2025	BUY	$258.78 - $328.31 $20,961 - $26,593	81 Added 0.2%	40,436 $10.5 Million
Q3 2024 Oct 11, 2024	BUY	$309.38 - $337.38 $9.51 Million - $10.4 Million	30,741 Added 319.75%	40,355 $13 Million
Q2 2024 Jul 11, 2024	SELL	$262.75 - $319.31 $6.61 Million - $8.03 Million	-25,144 Reduced 72.34%	9,614 $3 Million
Q1 2024 Apr 15, 2024	BUY	$268.87 - $324.56 $3.56 Million - $4.3 Million	13,241 Added 61.54%	34,758 $9.88 Million
Q4 2023 Jan 12, 2024	SELL	$255.7 - $288.46 $1.97 Million - $2.22 Million	-7,699 Reduced 26.35%	21,517 $6.2 Million
Q3 2023 Oct 17, 2023	BUY	$218.65 - $271.46 $392,258 - $486,999	1,794 Added 6.54%	29,216 $7.85 Million
Q2 2023 Jul 26, 2023	BUY	$214.27 - $253.37 $85,922 - $101,601	401 Added 1.48%	27,422 $6.09 Million
Q1 2023 May 04, 2023	BUY	$225.79 - $275.2 $1.01 Million - $1.23 Million	4,486 Added 19.91%	27,021 $6.53 Million
Q4 2022 Feb 03, 2023	BUY	$229.03 - $291.01 $552,649 - $702,207	2,413 Added 11.99%	22,535 $5.92 Million
Q3 2022 Nov 04, 2022	BUY	$224.46 - $253.15 $2.09 Million - $2.36 Million	9,320 Added 86.28%	20,122 $4.54 Million
Q2 2022 Aug 02, 2022	SELL	$230.71 - $256.74 $1.78 Million - $1.98 Million	-7,716 Reduced 41.67%	10,802 $2.63 Million
Q1 2022 May 09, 2022	SELL	$219.27 - $242.57 $833,664 - $922,251	-3,802 Reduced 17.03%	18,518 $4.48 Million
Q4 2021 Jan 18, 2022	BUY	$198.88 - $227.6 $1.52 Million - $1.74 Million	7,659 Added 52.24%	22,320 $5.02 Million
Q3 2021 Nov 10, 2021	SELL	$212.27 - $248.7 $60,496 - $70,879	-285 Reduced 1.91%	14,661 $3.12 Million
Q2 2021 Aug 04, 2021	SELL	$233.58 - $259.14 $94,599 - $104,951	-405 Reduced 2.64%	14,946 $3.64 Million
Q1 2021 Apr 15, 2021	SELL	$221.91 - $258.6 $2.36 Million - $2.75 Million	-10,631 Reduced 40.92%	15,351 $3.82 Million
Q4 2020 Jan 12, 2021	SELL	$216.38 - $257.67 $400,735 - $477,204	-1,852 Reduced 6.65%	25,982 $5.97 Million
Q3 2020 Oct 13, 2020	BUY	$234.65 - $260.95 $798,513 - $888,012	3,403 Added 13.93%	27,834 $7.07 Million
Q2 2020 Aug 06, 2020	BUY	$197.81 - $242.74 $267,241 - $327,941	1,351 Added 5.85%	24,431 $5.76 Million
Q1 2020 Apr 29, 2020	BUY	$182.24 - $241.7 $1.22 Million - $1.62 Million	6,716 Added 41.04%	23,080 $4.68 Million
Q4 2019 Jan 21, 2020	BUY	$189.21 - $243.2 $10,217 - $13,132	54 Added 0.33%	16,364 $3.95 Million
Q3 2019 Oct 10, 2019	BUY	$174.11 - $208.62 $650,126 - $778,987	3,734 Added 29.69%	16,310 $3.16 Million
Q2 2019 Jul 17, 2019	BUY	$166.7 - $195.41 $1.07 Million - $1.25 Million	6,390 Added 103.3%	12,576 $2.32 Million
Q1 2019 Apr 03, 2019	SELL	$180.87 - $203.88 $180 - $203	-1 Reduced 0.02%	6,186 $1.18 Million
Q4 2018 Jan 14, 2019	SELL	$178.4 - $208.25 $205,873 - $240,320	-1,154 Reduced 15.72%	6,187 $1.2 Million
Q3 2018 Oct 09, 2018	BUY	$185.29 - $208.89 $53,363 - $60,160	288 Added 4.08%	7,341 $1.52 Million
Q2 2018 Jul 12, 2018	BUY	$166.05 - $186.51 $365,808 - $410,881	2,203 Added 45.42%	7,053 $1.3 Million
Q2 2018 Jul 12, 2018	BUY	$166.05 - $186.51 $805,342 - $904,573	4,850 New	4,850 $827,000

Others Institutions Holding AMGN

# of Institutions

3,309

Shares Held

429M

Call Options Held

8.06M

Put Options Held

7.7M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $154B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cx Institutional, based on Form 13F filings with the SEC.

News

Stay updated on Cx Institutional with notifications on news.

Account

Cx Institutional Amgen Inc Transaction History